University of Vermont

College of Medicine

Department of Medicine

Cardiovascular Medicine

Bio for David Schneider, M.D.
David Schneider, M.D.

David Schneider, M.D.

Professor of Medicine
Director Cardiovascular Medicine, Department of Medicine


Contact Information
E-mail: David.Schneider@uvm.edu
Office Location:
Medicine, Colch Res Facil T-224

Education

Medical School - University of Cincinnati, OH

Research Interests

Delineated mechanisms responsible for altered fibrinolysis in the blood of patients with diabetes.  Demonstrated that the combination of hyperinsulinemia, hyperglycemia and increased concentrations of free fatty acids in blood of healthy subjects increases the concentration and activity of the primary inhibitor of fibrinolysis, plasminogen activator inhibitor type 1 (PAI-1).  With studies in vitro that demonstrated increased concentrations in blood of insulin increase expression of PAI-1 through stabilization of mRNA.  In addition demonstrated that free fatty acids increase expression of PAI-1 by increasing transcription of PAI-1 through a fatty acid response region in the 5’ untranslated region of the PAI-1 gene.


Developed and implemented a sensitive and specific assessment of platelet function that utilizes flow cytometry to characterize specific components of platelet reactivity.  Utilized this method to demonstrate the prognostic implications of platelet reactivity and to characterize the effects of selected condition, and treatments on platelet function.


Identified factors that influence platelet function by increasing platelet reactivity.

Academic Appointments

Professor of Medicine, University of Vermont
Director, Cardiovascular Division

Research Grants

   NIH: (U01 HL61744) “BARI 2D” - 1/01-12/07 Kathryn Detre, Principal Investigator, Schneider, Co-Investigator
   NIH: (R01 HL69146) "Mechanisms of Pro-Thrombosis in Diabetes Mellitus" - 7/01/01-12/31/05, Schneider, Principal Investigator

Publications

   Schneider DJ, Sobel BE:  Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-I:  Implications for vascular disease in hyperinsulinemic states.  Proc. Natl. Acad. Sci. USA 88:9959-9963, 1991.
   McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE:  Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.  Diabetes 43:104-109, 1994.
   Schneider DJ, Hayes M, Taatjes H, Wadsworth M, Rincon M, Taatjes DJ, Sobel BE: Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type-1 (PAI-1). J. Histochem. Cytochem. 52:1091-1099, 2004.

   Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM.  Association between Increased Platelet P-selectin Expression and Obesity in Patients with Type 2 Diabetes: A BARI 2D Sub-study.  Diabetes Care. 32:944-9, 2009
   KeatingFK, Butenas S, Fung MK, Schneider DJ.  Platelet-leukocyte interaction, leukocyte apoptosis and procoagulant activity in stored red blood cells. Transfusion, in press

For a complete listing of Dr. Schneider's publications go to http://scholar.google.com/citations?user=aiFR_rEAAAAJ&hl=en